🇺🇸 oxycodone prolonged release tablet in United States

6 US adverse-event reports

Safety signals — FAERS

Adverse reaction reports describe suspected side effects. A report does not mean the drug caused the event — co-medications, underlying disease and coincidence all contribute.

• Window: 28 March 2025 – 28 March 2026
• Total reports: 6

Most-reported reactions

1. Decreased Appetite — 1 report (16.67%)
2. Gastric Disorder — 1 report (16.67%)
3. Hiatus Hernia — 1 report (16.67%)
4. Melaena — 1 report (16.67%)
5. Nausea — 1 report (16.67%)
6. Retching — 1 report (16.67%)

Source database →

Frequently asked questions

Is oxycodone prolonged release tablet approved in United States?

oxycodone prolonged release tablet does not currently have US marketing authorisation in our dataset.

Who is the marketing authorisation holder for oxycodone prolonged release tablet in United States?

Mundipharma Research GmbH & Co KG is the originator. The local marketing authorisation holder may differ — check the official source linked above.